Merck to Buy Idenix for $3.9B for Hepatitis C Drugs

June 9 (Bloomberg) -- Merck & Co. agreed to buy Idenix Pharmaceuticals Inc. for about $3.85 billion to add experimental drugs to treat hepatitis C. Adam Johnson reports on Bloomberg Television’s “Bloomberg Surveillance.” (Source: Bloomberg)

The Mixed Messages Out of Australia's Economy
12:29 - Sean Fenton, Tribeca Investment Partners portfolio manager, discusses the state of Australia's economy and the outlook for RBA policy with Bloomberg's Rishaad Salamat on "Trending Business." (Source: Bloomberg)
  • Malaysia to Complete 1MDB Investigations in Few Months
  • Bombardier Is an Excellent Company: Andre Desmarais
  • Apple Pay, UnionPay Said to Reach Deal in China